[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 572,783
  • Shares Outstanding, K 53,833
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -244,090 K
  • EBIT $ -215 M
  • EBITDA $ -211 M
  • 60-Month Beta -0.23
  • Price/Sales 61.48
  • Price/Cash Flow N/A
  • Price/Book 2.12

Options Overview Details

View History
  • Implied Volatility 87.36% (-1.14%)
  • Historical Volatility 44.38%
  • IV Percentile 29%
  • IV Rank 13.78%
  • IV High 339.95% on 11/19/25
  • IV Low 47.00% on 12/17/25
  • Expected Move (DTE 11) 0.77 (7.19%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 5
  • Volume Avg (30-Day) 280
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 11,060
  • Open Int (30-Day) 8,607
  • Expected Range 9.88 to 11.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 3
  • High Estimate $-0.23
  • Low Estimate $-0.38
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) +72.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.51 +11.88%
on 04/02/26
11.57 -8.04%
on 04/28/26
+0.61 (+6.08%)
since 04/01/26
3-Month
8.19 +29.84%
on 02/20/26
11.57 -8.04%
on 04/28/26
+1.83 (+20.77%)
since 01/30/26
52-Week
4.32 +146.30%
on 05/28/25
11.69 -8.98%
on 10/28/25
+1.92 (+22.02%)
since 05/01/25

Most Recent Stories

More News
Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.64 (-3.80%)
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Coramitug is being evaluated by...

PRTA : 10.64 (-3.80%)
Prothena Announces Leadership Team Updates

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates...

PRTA : 10.64 (-3.80%)
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner...

PRTA : 10.64 (-3.80%)
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million...

PRTA : 10.64 (-3.80%)
Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.64 (-3.80%)
Prothena: Q4 Earnings Snapshot

Prothena: Q4 Earnings Snapshot

PRTA : 10.64 (-3.80%)
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4...

PRTA : 10.64 (-3.80%)
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.64 (-3.80%)
Prothena Announces Board of Directors Update

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.64 (-3.80%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 11.47
2nd Resistance Point 11.30
1st Resistance Point 10.97
Last Price 10.64
1st Support Level 10.48
2nd Support Level 10.31
3rd Support Level 9.98

See More

52-Week High 11.69
Last Price 10.64
Fibonacci 61.8% 8.87
Fibonacci 50% 8.01
Fibonacci 38.2% 7.14
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.